Heska to Present at the 7th Annual Fall Growth Stock Conference Hosted by Security Research Associates, Inc.

LOVELAND, Colo., Nov. 2, 2011 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA), a provider of advanced veterinary diagnostic and other specialty veterinary products, today announced that Robert Grieve, Heska's Chairman and CEO, will present at the 7th Annual Fall Growth Stock Conference hosted by Security Research Associates, Inc. ("SRA"). The conference will be held on Tuesday, November 15, at the Le Meridien Hotel in San Francisco.  

Conference attendees will include a select group of institutional portfolio managers and analysts, and will feature CEOs and CFOs from some of the fastest growing companies in the technology and life sciences sectors. SRA has arranged for webcasting of company presentations during this event. To access the lobby page for the webcast of presenting companies please go to: http://www.videonewswire.com/event.asp?id=82625.

Dr. Grieve commented, "We look forward to articulating Heska's opportunity to the professional investment community. We have a strong base of recurring revenue, more than $1 per share in cash and no debt. In addition, our commercial network is expanding, targeting a large market opportunity with favorable demographics."

About Security Research Associates, Inc.

SRA was founded in San Francisco in 1980 and, today, offers investment banking and M&A services as well as institutional brokerage services. A boutique firm by design, SRA works with a select group of portfolio managers from around the country and focuses on technology and life science companies in the micro and small cap arenas. For more information about SRA see our web site at www.sracap.com or call us at 415-925-0346.

About Heska

Heska Corporation (NASDAQ: HSKA) sells advanced veterinary diagnostic and other specialty veterinary products. Heska's state-of-the-art offerings to its customers include diagnostic instruments and supplies as well as single use, point-of-care tests, pharmaceuticals and vaccines. The company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians. For further information on Heska and its products, visit the company's website at www.heska.com.

Forward-Looking Statements

This announcement contains forward-looking statements regarding Heska's future financial and operating results. For example, Dr. Grieve's stated expectations for new product launches are forward-looking.  These statements are based on current expectations and are subject to a number of risks and uncertainties. Investors should note that there is an inherent risk in using past results, including trends, to predict future outcomes.  In addition, factors that could affect the business and financial results of Heska generally include the following: risks related to Heska's reliance on third parties to develop certain of Heska's future products; risks related to Heska's ability to increase the productivity of its sales force; risks related to the implementation of current product development plans, including anticipated launch dates; risks regarding Heska's reliance on third-party suppliers such as minimum purchase requirements, which could have a significant adverse impact on Heska's financial position; uncertainties related to Heska's ability to hire and retain effective individuals to fill currently vacant positions; uncertainties related to Heska's ability to successfully commercialize new products; uncertainties regarding Heska's reliance on third parties to whom Heska has granted substantial marketing rights to certain of Heska's existing products and who may be large Heska customers, including Schering-Plough Animal Health Corporation which has exclusive rights to Heska's heartworm preventive in the United States; uncertainties regarding Heska's ability to successfully market and sell its products in an economically sustainable manner; competition; risks related to Heska's ability to generate levels of profitability to utilize significantly its deferred tax assets; and the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Quarterly Report on Form 10-Q for the quarter ended June 30, 2011.

SOURCE Heska Corporation